Archive


Category: EMERGE

  • The US FDA’s Advisory Panel Slams Biogen’s Aducanumab for Alzheimer’s Disease

    Shots: The advisory committee voted 1-8, with 2 members voting uncertain that EMERGE study (without regard for ENGAGE study) provides strong evidence, supporting the effectiveness of aducanumab as a treatment for AD. The committee also voted 0-7 with 4 members voting uncertain that PRIME study provides supporting evidence for aducanumab The committee voted 5-0 and […]